These press releases are for business and financial media.
-
-
- Press release archive 2009
- 16 October 2009
- SYMBICORT TURBUHALER Approved for the Treatment of Adult Asthma in Japan AstraZeneca today announced that Symbicort Turbuhaler (budesonide/formoterol) has been approved by Japan’s Ministry of Health, Labor and Welfare (MHLW) for the maintenance treatment of bronchial asthma in patients aged 16 and over when a combination therapy of an inhaled steroid and a long-acting beta-2 agonist is necessary.
-
-
-
- Press release archive 2009
- 02 October 2009
- Dapagliflozen Study Demonstrated Significantly Improved Glycemic Control and Weight Reduction in Type 2 Diabetes Patients Inadequately Controlled with Metformin Results from a 24-week phase 3 clinical study demonstrated that the investigational drug dapagliflozin, added to metformin, demonstrated significant mean reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c) and in the secondary endpoint, fasting plasma glucose (FPG) in patients with type 2 diabetes inadequately controlled with metformin alone, as compared to placebo plus metformin.
-
-
-
- Press release archive 2009
- 06 April 2009
- AstraZeneca Receives FDA Complete Response Letter on Symbicort for the Treatment of Asthma in Children 6 to 11 Years Old AstraZeneca today announced the company has received a Complete Response Letter from the US Food and Drug Administration for SYMBICORT pressurized metered dose inhaler for the long-term maintenance treatment of asthma in pediatric patients ages 6-11 years.
-
-
-
- Press release archive 2009
- 24 February 2009
- AstraZeneca’s Partner, MAP Pharmaceuticals, Announces Phase III Study Of Unit Dose Budesonide In Children With Asthma Did Not Meet Primary Endpoints MAP Pharmaceuticals, Inc. announced yesterday that its initial Phase III clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma did not meet its co-primary endpoints: asthma control as assessed by changes from baseline in night-time and daytime composite symptom scores, in either of the doses evaluated when compared with placebo.
-
-
-
- Press release archive 2009
- 04 June 2009
- AstraZeneca and Abbott Submit New Drug Application to the FDA for the Approval of CERTRIAD for the Treatment of Mixed Dyslipidemia AstraZeneca and Abbott announced today that the companies have submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including high LDL cholesterol (the “bad” cholesterol), high triglycerides and low HDL-cholesterol (the “good” cholesterol).
-
-
-
- Press release archive 2009
- 28 October 2009
- AstraZeneca withdraws regulatory submissions for Zactima (vandetanib) in combination with chemotherapy for advanced NSCLC AstraZeneca announced today that it has withdrawn the regulatory submissions for the use of ZACTIMA (vandetanib) 100mg in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) from the US FDA and the European Medicines Agency (EMEA). The applications were submitted to regulatory agencies in June 2009.
-
-
-
- Press release archive 2009
- 11 May 2009
- AstraZeneca Announces Top Line Results From Pivotal Phase III Study for BRILINTA AstraZeneca today announced top line results from the phase III trial, PLATO, which demonstrate that BRILINTA, the investigational oral antiplatelet treatment for acute coronary syndromes (ACS), has achieved a statistically significant primary efficacy endpoint versus clopidogrel, in the prevention of cardiovascular (CV) events in patients with ACS.
-
-
-
- Press release archive 2009
- 02 April 2009
- ONGLYZA (Saxagliptin) Cardiovascular Profile Acceptable According to FDA Advisory Committee AstraZeneca and Bristol-Myers Squibb today announced that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee determined (by a vote of 10 to 2) that the data supporting the new drug application for ONGLYZA (saxagliptin) for the treatment of adults with type 2 diabetes were sufficient to rule out unacceptable cardiovascular risk relative to comparators in the programme.
-
-
-
- Press release archive 2009
- 04 March 2009
- AstraZeneca Issues 2008 Annual Report AstraZeneca has today published its Annual Report and Form 20-F Information 2008.
-
-
-
- Press release archive 2009
- 05 October 2009
- Study Finds That ONGLYZA (saxagliptin) When Added to Metformin was Non-Inferior to Januvia (sitagliptin) When Added to Metformin in Reducing Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus Results from an 18-week phase IIIb study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy alone found that the addition of treatment with ONGLYZA (saxagliptin) 5 mg per day achieved the primary objective of demonstrating non-inferiority compared to the addition of treatment with JANUVIA (sitagliptin) 100 mg per day in reducing HbA1c from baseline.
-
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD - Stockholm
-
310.10 SEK
At 21-Nov-2009 04:47 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
